The biopharma and med-tech sectors show evolving financing dynamics. Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, trailing 2024 but surpassing post-pandemic lows of prior years. Med-tech funding modestly rebounded to $18.11 billion in the same period. Notable capital raises include Heartflow's $317 million IPO, Minghui Pharmaceutical's $131 million pre-IPO round for antibody and ADC programs, and Tempus AI's 90% revenue growth driven by diagnostics sales. These financial flows underscore sustained investor interest amid sector-specific challenges.